These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28804776)

  • 1. Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis.
    Abdel-Rahman O; ElHalawani H; Ahmed H
    J Glob Oncol; 2015 Dec; 1(2):73-82. PubMed ID: 28804776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H; Ahmed H
    Future Oncol; 2015; 11(24):3307-19. PubMed ID: 26561878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials.
    Yang Y; Liu YH; Sun X; Yu MW; Yang L; Cheng PY; Yang GW; Wang XM
    Curr Med Res Opin; 2017 Sep; 33(9):1663-1675. PubMed ID: 28665153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
    Abdel-Rahman O; ElHalawani H
    Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Opin Drug Saf; 2014 Aug; 13(8):999-1008. PubMed ID: 24930544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis.
    Abdel-Rahman O; ElHalawani H
    Chemotherapy; 2014; 60(5-6):325-33. PubMed ID: 26302785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
    Miller CR; Oliver KE; Farley JH
    Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials.
    Wang ZY; Shi SY; Li SJ; Chen F; Chen H; Lin HZ; Lin JM
    Pain Med; 2015 Jul; 16(7):1373-85. PubMed ID: 26176791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence based evaluation of immuno-coagulatory interventions in critical care.
    Afshari A
    Dan Med Bull; 2011 Sep; 58(9):B4316. PubMed ID: 21893014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled corticosteroids in children with persistent asthma: effects on growth.
    Zhang L; Prietsch SO; Ducharme FM
    Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
    Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
    Zaman K; Winterhalder R; Mamot C; Hasler-Strub U; Rochlitz C; Mueller A; Berset C; Wiliders H; Perey L; Rudolf CB; Hawle H; Rondeau S; Neven P
    Eur J Cancer; 2015 Jul; 51(10):1212-20. PubMed ID: 25892646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
    Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
    Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells.
    Koukorava C; Ahmed K; Almaghrabi S; Pointon A; Haddrick M; Cross MJ
    Front Cardiovasc Med; 2024; 11():1372817. PubMed ID: 39081368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
    Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
    Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
    Stathis A; Tolcher AW; Wang JS; Renouf DJ; Chen LC; Suttner LH; Freshwater T; Webber AL; Nayak T; Siu LL
    Invest New Drugs; 2023 Jun; 41(3):380-390. PubMed ID: 37040046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.